With the obesity numbers for Eli Lilly’s retatrutide already stacking up nicely, the company has rounded out its pitch for the triple agonist with top-line data on its ability to lower blood sugar ...

Adding a fourth oral antidiabetic drug to a triple regimen beats metformin dose escalation for achieving glycemic control.

Indianapolis-based Eli Lilly just logged another big win in the metabolic medicine race, reporting that its experimental triple-agonist drug retatrutide cleared a late-stage trial in people with type ...

Twenty-five people have credited the people and partners behind Raising Hope for saving or significantly improving their ...

Individuals with a higher estimated basal metabolic rate face a greater chance of developing diabetes and many of its ...